|
1
|
Longhi A, Errani C, De Paolis M, Mercuri M
and Bacci G: Primary bone osteosarcoma in the pediatric age: State
of the art. Cancer Treat Rev. 32:4234362006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He H, Ni J and Huang J: Molecular
mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett.
7:135213622014. View Article : Google Scholar
|
|
3
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:302930352015. View Article : Google Scholar
|
|
4
|
Santer FR, Höschele PP, Oh SJ, Erb HHH,
Bouchal J, Cavarretta IT, Parson W, Meyers DJ, Cole PA and Culig Z:
Inhibition of the acetyltransferases p300 and CBP reveals a
targetable function for p300 in the survival and invasion pathways
of prostate cancer cell lines. Mol Cancer Ther. 10:1644–1655. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang
LJ and Yang HX: High expression of the transcriptional co-activator
p300 predicts poor survival in resectable non-small cell lung
cancers. Eur J Surg Oncol. 38:523–530. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang J, Wu M, Zheng D, Zhang H, Lv Y,
Zhang L, Tan HS, Zhou H, Lao YZ and Xu HX: Garcinol inhibits
esophageal cancer metastasis by suppressing the p300 and TGF-β1
signaling pathways. Acta Pharmacol Sin. 41:82–92. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang W, Li M, Wang L, Chen L and Goh BC:
Curcumin in cancer therapy: Exploring molecular mechanisms and
overcoming clinical challenges. Cancer Lett. 570:2163322023.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mundekkad D and Cho WC: Applications of
curcumin and its nanoforms in the treatment of cancer.
Pharmaceutics. 15:22232023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Balasubramanyam K, Varier RA, Altaf M,
Swaminathan V, Siddappa NB, Ranga U and Kundu TK: Curcumin, a novel
p300/CREB-binding protein-specific inhibitor of acetyltransferase,
represses the acetylation of histone/nonhistone proteins and
histone acetyltransferase-dependent chromatin transcription. J Biol
Chem. 279:51163–51171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu X, Li Q, Chang R, Yang D, Song Z, Guo
Q and Huang C: Curcumin alleviates neuropathic pain by inhibiting
p300/CBP histone acetyltransferase activity-regulated expression of
BDNF and cox-2 in a rat model. PLoS One. 9:e913032014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sunagawa Y, Funamoto M, Shimizu K, Shimizu
S, Sari N, Katanasaka Y, Miyazaki Y, Kakeya H, Hasegawa K and
Morimoto T: Curcumin, an inhibitor of p300-HAT activity, suppresses
the development of hypertension-induced left ventricular
hypertrophy with preserved ejection fraction in dahl rats.
Nutrients. 13:26082021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meiyanto E, Putri DD, Susidarti RA,
Murwanti R, Sardjiman Fitriasari A, Husnaa U, Purnomo H and
Kawaichi M: Curcumin and its analogues (PGV-0 and PGV-1) enhance
sensitivity of resistant MCF-7 cells to doxorubicin through
inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev.
15:179–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Novitasari D, Jenie RI, Kato JY and
Meiyanto E: The integrative bioinformatic analysis deciphers the
predicted molecular target gene and pathway from curcumin
derivative CCA-1.1 against triple-negative breast cancer (TNBC). J
Egypt Natl Canc Inst. 33:192021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Utomo RY, Wulandari F, Novitasari D,
Lestari B, Susidarti RA, Jenie RI, Kato JY, Sardjiman S and
Meiyanto E: Preparation and cytotoxic evaluation of PGV-1
derivative, CCA-1.1, as a new curcumin analog with
improved-physicochemical and pharmacological properties. Adv Pharm
Bull. 12:6036122022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lestari B, Nakamae I, Yoneda-Kato N,
Morimoto T, Kanaya S, Yokoyama T, Shionyu M, Shirai T, Meiyanto E
and Kato JY: Pentagamavunon-1 (PGV-1) inhibits ROS metabolic
enzymes and suppresses tumor cell growth by inducing M phase
(prometaphase) arrest and cell senescence. Sci Rep. 9:148672019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wulandari F, Ikawati M, Widyarini S,
Kirihata M, Novitasari D, Kato JY and Meiyanto E:
Tumour-suppressive effects of curcumin analogs CCA-1.1 and
Pentagamavunone-1 in colon cancer: In vivo and in vitro studies. J
Adv Pharm Technol Res. 14:317–324. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu C, Wang M, Guo W, Sun W and Liu Y:
Curcumin in osteosarcoma therapy: Combining with immunotherapy,
chemotherapeutics, bone tissue engineering materials and potential
synergism with photodynamic therapy. Front Oncol. 11:6724902021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zahedipour F, Bolourinezhad M, Teng Y and
Sahebkar A: The multifaceted therapeutic mechanisms of curcumin in
osteosarcoma: State-of-the-art. J Oncol. 2021:30068532021.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu KH, Lu PW, Lin CW and Yang SF: Curcumin
in human osteosarcoma: From analogs to carriers. Drug Discov Today.
28:1034372023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iwata S, Tatsumi Y, Yonemoto T, Araki A,
Itami M, Kamoda H, Tsukanishi T, Hagiwara Y, Kinoshita H, Ishii T,
et al: CDK4 overexpression is a predictive biomarker for resistance
to conventional chemotherapy in patients with osteosarcoma. Oncol
Rep. 46:1352021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Strober W: Trypan blue exclusion test of
cell viability. Curr Protoc Immunol Appendix 3: Appendix 3B.
2001.PubMed/NCBI
|
|
22
|
Yang H, Pinello CE, Luo J, Li D, Wang Y,
Zhao LY, Jahn SC, Saldanha SA, Chase P, Planck J, et al:
Small-molecule inhibitors of acetyltransferase p300 identified by
high-throughput screening are potent anticancer agents. Mol Cancer
Ther. 12:610–620. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tatsumi Y, Takano R, Islam MS, Yokochi T,
Itami M, Nakamura Y and Nakagawara A: BMCC1, which is an
interacting partner of BCL2, attenuates AKT activity, accompanied
by apoptosis. Cell Death Dis. 6:e16072015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meiyanto E, Putri H, Arum Larasati Y, Yudi
Utomo R, Istighfari Jenie R, Ikawati M, Lestari B, Yoneda-Kato N,
Nakamae I, Kawaichi M and Kato JY: Anti-proliferative and
anti-metastatic potential of curcumin analogue, pentagamavunon-1
(PGV-1), toward highly metastatic breast cancer cells in
correlation with ROS generation. Adv Pharm Bull. 9:445–452. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meiyanto E, Husnaa U, Kastian RF, Putri H,
Larasati YA, Khumaira A, Pamungkas DDP, Jenie RI, Kawaichi M,
Lestari B, et al: The target differences of anti-tumorigenesis
potential of curcumin and its analogues against HER-2 positive and
triple-negative breast cancer cells. Adv Pharm Bull. 11:188–196.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Endah E, Wulandari F, Putri Y, Jenie RI
and Meiyanto E: Piperine increases Pentagamavunon-1 anti-cancer
activity on 4T1 breast cancer through mitotic catastrophe mechanism
and senescence with sharing targeting on mitotic regulatory
proteins. Iran J Pharm Res. 21:e1238202022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kamitani N, Nakamae I, Yoneda-Kato N, Kato
JY and Sho M: Preclinical evaluation of pentagamavunone-1 as
monotherapy and combination therapy for pancreatic cancer in
multiple xenograft models. Sci Rep. 12:224192022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hermawan A, Wulandari F, Hanif N, Utomo
RY, Jenie RI, Ikawati M and Tafrihani AS: Identification of
potential targets of the curcumin analog CCA-1.1 for glioblastoma
treatment: Integrated computational analysis and in vitro study.
Sci Rep. 12:139282022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Novitasari D, Jenie RI, Kato JY and
Meiyanto E: Chemoprevention curcumin analog 1.1 promotes metaphase
arrest and enhances intracellular reactive oxygen species levels on
TNBC MDA-MB-231 and HER2-positive HCC1954 cells. Res Pharm Sci.
18:358–370. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ryu K, Choy E, Yang C, Susa M, Hornicek
FJ, Mankin H and Duan Z: Activation of signal transducer and
activator of transcription 3 (Stat3) pathway in osteosarcoma cells
and overexpression of phosphorylated-Stat3 correlates with poor
prognosis. J Orthop Res. 28:971–978. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kelly B, Thamm D and Rosengren RJ: The
second-generation curcumin analogue RL71 elicits G2/M cell cycle
arrest and apoptosis in canine osteosarcoma cells. Vet Comp Oncol.
21:595–604. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee DS, Lee MK and Kim JH: Curcumin
induces cell cycle arrest and apoptosis in human osteosarcoma (HOS)
cells. Anticancer Res. 29:5039–5044. 2009.PubMed/NCBI
|
|
33
|
Kabir MT, Rahman MH, Akter R, Behl T,
Kaushik D, Mittal V, Pandey P, Akhtar MF, Saleem A, Albadrani GM,
et al: Potential role of curcumin and its nanoformulations to treat
various types of cancers. Biomolecules. 11:3922021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu KH, Lu PW, Lu EW, Lin CW and Yang SF:
Curcumin and its analogs and carriers: Potential therapeutic
strategies for human osteosarcoma. Int J Biol Sci. 19:1241–1265.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marcu MG, Jung YJ, Lee S, Chung EJ, Lee
MJ, Trepel J and Neckers L: Curcumin is an inhibitor of p300
histone acetylatransferase. Med Chem. 2:169–174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Szerlong HJ, Prenni JE, Nyborg JK and
Hansen JC: Activator-dependent p300 acetylation of chromatin in
vitro: Enhancement of transcription by disruption of repressive
nucleosome-nucleosome interactions. J Biol Chem.
285:31954319642010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Raisner R, Kharbanda S, Jin L, Jeng E,
Chan E, Merchant M, Haverty PM, Bainer R, Cheung T, Arnott D, et
al: Enhancer activity requires CBP/P300 bromodomain-dependent
histone H3K27 acetylation. Cell Rep. 24:1722–1729. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hogg SJ, Motorna O, Cluse LA, Johanson TM,
Coughlan HD, Raviram R, Myers RM, Costacurta M, Todorovski I,
Pijpers L, et al: Targeting histone acetylation dynamics and
oncogenic transcription by catalytic P300/CBP inhibition. Mol Cell.
81:2183–2200.e13. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Narita T, Ito S, Higashijima Y, Chu WK,
Neumann K, Walter J, Satpathy S, Liebner T, Hamilton WB, Maskey E,
et al: Enhancers are activated by p300/CBP activity-dependent PIC
assembly, RNAPII recruitment, and pause release. Mol Cell.
81:2166–2182.e6. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen M, Qian C, Jin B, Hu C, Zhang L, Wang
M, Zhou B, Zuo W, Huang L and Wang Y: Curcumin analog WZ26 induces
ROS and cell death via inhibition of STAT3 in cholangiocarcinoma.
Cancer Biol Ther. 24:21628072023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li L, Chen M, Li G and Cai R: Raddeanin A
induced apoptosis of non-small cell lung cancer cells by promoting
ROS-mediated STAT3 inactivation. Tissue Cell. 71:1015772021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Alsamri H, Hasasna HE, Baby B, Alneyadi A,
Dhaheri YA, Ayoub MA, Eid AH, Vijayan R and Iratni R: Canosol is
novel inhibitor of p300 acetyltransferase in breast cancer. Front
Oncol. 11:6644032021. View Article : Google Scholar : PubMed/NCBI
|
